Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Viral triggers of multiple sclerosis.
Zist Daru, ZIFERON
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
Recruiting women smokers: the engineering of consent.
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system.
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Temporal trends in the incidence of multiple sclerosis: a systematic review.
Gender as risk factor for autoimmune diseases.

Pages